Fox Hill Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Fox Hill Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Buy	629 +4	+0.6%	+$1.77K	0.13%	93
2026 Q1	$279K	Hold	625	–	–	0.13%	93
2025 Q4	$283K	Sell	625 -24	-4%	-$10.3K	0.13%	90
2025 Q3	$254K	Sell	649 -34	-5%	-$14.2K	0.12%	98
2025 Q2	$304K	Buy	683 +6	+0.9%	+$2.77K	0.16%	86
2025 Q1	$328K	Sell	677 -1	-0.1%	-$466	0.19%	79
2024 Q4	$273K	Sell	678 -15	-2%	-$6.95K	0.15%	84
2024 Q3	$322K	Buy	693 +25	+4%	+$12K	0.18%	80
2024 Q2	$313K	Sell	668 -19	-3%	-$8.25K	0.19%	74
2024 Q1	$287K	Buy	687 +15	+2%	+$6.34K	0.19%	82
2023 Q4	$273K	Buy	+672	New	+$248K	0.21%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fox Hill Wealth Management's VRTX Position: Q2 2026 in Review

Fox Hill Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.64% in Q2 2026, buying an estimated $1.77K and bringing the position to 629 shares worth $312K. The position accounts for 0.13% of the portfolio, ranked #93.

Fox Hill Wealth Management first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $328K in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Fox Hill Wealth Management held 629 shares of Vertex Pharmaceuticals worth $312K as of Q2 2026.
Fox Hill Wealth Management bought 4 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.77K.
Vertex Pharmaceuticals made up 0.13% of Fox Hill Wealth Management's portfolio in Q2 2026, its #93 holding.
Fox Hill Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Fox Hill Wealth Management's Vertex Pharmaceuticals position peaked at $328K in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fox Hill Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.